Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Crinetics Pharmaceuticals (CRNX) Invested Capital (2017 - 2025)

Historic Invested Capital for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Q3 2025 value amounting to $1.1 billion.

  • Crinetics Pharmaceuticals' Invested Capital rose 2871.49% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 2871.49%. This contributed to the annual value of $1.3 billion for FY2024, which is 14574.11% up from last year.
  • As of Q3 2025, Crinetics Pharmaceuticals' Invested Capital stood at $1.1 billion, which was up 2871.49% from $1.2 billion recorded in Q2 2025.
  • Over the past 5 years, Crinetics Pharmaceuticals' Invested Capital peaked at $1.3 billion during Q4 2024, and registered a low of $149.5 million during Q1 2021.
  • In the last 5 years, Crinetics Pharmaceuticals' Invested Capital had a median value of $386.2 million in 2022 and averaged $590.3 million.
  • In the last 5 years, Crinetics Pharmaceuticals' Invested Capital tumbled by 3419.5% in 2023 and then skyrocketed by 22692.27% in 2024.
  • Crinetics Pharmaceuticals' Invested Capital (Quarter) stood at $331.9 million in 2021, then decreased by 4.7% to $316.3 million in 2022, then surged by 70.43% to $539.1 million in 2023, then soared by 145.74% to $1.3 billion in 2024, then decreased by 19.07% to $1.1 billion in 2025.
  • Its Invested Capital stands at $1.1 billion for Q3 2025, versus $1.2 billion for Q2 2025 and $1.3 billion for Q1 2025.